Related Experiment Video

Updated: May 31, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222

M Acunzo1, R Visone, G Romano

  • 1Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA.

Oncogene
|June 28, 2011
PubMed

Insights

This study reveals that miR-130a targets MET, reducing resistance to TNF-related apoptosis-inducing ligand (TRAIL) in non-small cell lung cancer (NSCLC). This finding offers new therapeutic strategies for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Non-small cell lung cancer (NSCLC) remains a significant health challenge with poor patient survival despite therapeutic advances.
  • The MET proto-oncogene upregulates miR-221 and miR-222, promoting NSCLC cell survival and resistance to TNF-related apoptosis-inducing ligand (TRAIL) by downregulating p27(kip1), PTEN, and TIMP3.

Purpose of the Study:

  • To investigate the regulatory role of miR-130a in the MET-mediated pathway involved in NSCLC drug resistance.
  • To explore the potential of targeting this pathway for novel NSCLC therapeutic strategies.

Main Methods:

  • Investigated the effect of miR-130a on MET expression in NSCLC cell lines.
  • Analyzed the impact of miR-130a on TRAIL resistance and cell migration.
  • Examined the role of c-Jun in mediating the downregulation of miR-221 and miR-222 by miR-130a.

Main Results:

  • miR-130a, expressed at low levels in NSCLC, targets MET, thereby reducing TRAIL resistance.
  • miR-130a induces c-Jun-mediated downregulation of miR-221 and miR-222.
  • miR-130a was found to reduce the migratory capacity of NSCLC cells.

Conclusions:

  • Understanding the MET-miR-221/222 axis regulation is crucial for developing effective NSCLC therapies.
  • miR-130a represents a potential therapeutic target for overcoming drug resistance and reducing metastasis in NSCLC.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...